Philips delivers strong ESG performance in 2023 20-02-2024, 15:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

eXp Realty Debuts Co-Sponsor Program, Accelerating the Future of Collaborative Agent Growth 2-04-2025, 21:00